NASDAQ:TRVN Trevena (TRVN) Stock Forecast, Price & News $0.65 +0.01 (+1.70%) (As of 01:45 PM ET) Add Compare Share Share Today's Range$0.65▼$0.6650-Day Range$0.64▼$1.0252-Week Range$0.54▼$5.13Volume9,877 shsAverage Volume1.23 million shsMarket Capitalization$8.94 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Trevena MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside751.4% Upside$5.50 Price TargetShort InterestBearish8.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.10) to ($1.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.73 out of 5 stars 3.5 Analyst's Opinion Consensus RatingTrevena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Trevena has a forecasted upside of 751.4% from its current price of $0.65.Amount of Analyst CoverageTrevena has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.42% of the float of Trevena has been sold short.Short Interest Ratio / Days to CoverTrevena has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Trevena has recently increased by 207.48%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTrevena does not currently pay a dividend.Dividend GrowthTrevena does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRVN. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Trevena this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for TRVN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows3 people have added Trevena to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevena insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Trevena is held by insiders.Percentage Held by InstitutionsOnly 4.95% of the stock of Trevena is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Trevena are expected to grow in the coming year, from ($2.10) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevena is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevena is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevena has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Trevena (NASDAQ:TRVN) StockTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.Read More TRVN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRVN Stock News HeadlinesSeptember 13, 2023 | fool.comTrevena (NASDAQ: TRVN)September 8, 2023 | bizjournals.comLab Notes: Trevena gets $15M triggered by first sale of drug in China; Braeburn launches opioid use disorder drug BrixadiSeptember 27, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 6, 2023 | marketwatch.comTrevena Shares Rise 18% After Getting $15M TrancheSeptember 6, 2023 | theglobeandmail.comBiotech Shares Are Running Again!September 6, 2023 | benzinga.comWhy Is Neurology Focused Trevena Stock Trading Higher Today?September 6, 2023 | msn.comTrevena gets $15M tranche after first commercial sale of OLINVYK in ChinaSeptember 6, 2023 | finance.yahoo.comTrevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target EngagementSeptember 27, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 6, 2023 | finance.yahoo.comTrevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business UpdateAugust 14, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on Trevena (TRVN)August 14, 2023 | finanznachrichten.deTrevena, Inc.: Trevena Reports Second Quarter 2023 Results and Provides Business UpdateAugust 14, 2023 | finance.yahoo.comTrevena Reports Second Quarter 2023 Results and Provides Business UpdateJuly 20, 2023 | finance.yahoo.comTrevena, Inc. Appoints Mark Corrigan, M.D. to Board of DirectorsJune 26, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Femasys (FEMY) and Trevena (TRVN)June 26, 2023 | finance.yahoo.comTrevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes StudyJune 15, 2023 | ca.finance.yahoo.comTRVN - Trevena, Inc.May 31, 2023 | finance.yahoo.comTrevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa PharmaceuticalMay 30, 2023 | markets.businessinsider.comTrevena Achieves Listing Compliance On NasdaqMay 30, 2023 | finanznachrichten.deTrevena, Inc.: Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term MilestonesMay 30, 2023 | finance.yahoo.comTrevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term MilestonesMay 18, 2023 | msn.comJMP Securities Reiterates Trevena (TRVN) Market Outperform RecommendationMay 16, 2023 | markets.businessinsider.comJMP Securities Sticks to Their Buy Rating for Trevena (TRVN)May 12, 2023 | msn.comTrevena Earnings PreviewMay 12, 2023 | bizjournals.comLab Notes: Trevena receives $3M payment; Wayne firm raises $7.2MMay 12, 2023 | msn.comTrevena Q1 Earnings PreviewMay 11, 2023 | msn.comOliver Trevena Signs First-Look Unscripted Deal With MAK PicturesSee More Headlines Receive TRVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter. Email Address TRVN Company Calendar Last Earnings8/14/2023Today9/27/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRVN CUSIPN/A CIK1429560 Webwww.trevena.com Phone(610) 354-8840FaxN/AEmployees35Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.50 High Stock Price Forecast$9.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+743.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,670,000.00 Net MarginsN/A Pretax Margin-1,461.22% Return on Equity-265.73% Return on Assets-86.25% Debt Debt-to-Equity Ratio1.45 Current Ratio4.03 Quick Ratio3.92 Sales & Book Value Annual Sales$570,000.00 Price / Sales15.69 Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / Book0.29Miscellaneous Outstanding Shares13,710,000Free Float13,260,000Market Cap$8.94 million OptionableOptionable Beta1.91 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMs. Carrie L. Bourdow (Age 60)Pres, CEO & Director Comp: $1MMr. Barry Shin (Age 51)Sr. VP & CFO Comp: $670.02kDr. Mark A. Demitrack (Age 65)Sr. VP & Chief Medical Officer Comp: $690.32kDr. Howard A. Rockman M.D.Scientific Founder, Consultant and Member of Scientific Advisory BoardMr. Joel SolomonVP, Gen. Counsel & Chief Compliance OfficerMr. Michael CatalanoVP of MarketingMr. Robert T. Yoder (Age 57)Sr. VP, Chief Bus. Officer & Head of Commercial Operations Ms. Patricia M. Drake (Age 57)Sr. VP & Chief Commercial Officer More ExecutivesKey CompetitorsCyclerion TherapeuticsNASDAQ:CYCNCohBarNASDAQ:CWBRXenetic BiosciencesNASDAQ:XBIOIterum TherapeuticsNASDAQ:ITRMCadrenal TherapeuticsNASDAQ:CVKDView All CompetitorsInstitutional OwnershipCitadel Advisors LLCBought 20,900 shares on 8/15/2023Ownership: 0.000%Renaissance Technologies LLCBought 111,620 shares on 8/11/2023Ownership: 1.660%View All Institutional Transactions TRVN Stock - Frequently Asked Questions Should I buy or sell Trevena stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRVN shares. View TRVN analyst ratings or view top-rated stocks. What is Trevena's stock price forecast for 2023? 2 Wall Street analysts have issued 12 month price objectives for Trevena's stock. Their TRVN share price forecasts range from $2.00 to $9.00. On average, they expect the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 743.3% from the stock's current price. View analysts price targets for TRVN or view top-rated stocks among Wall Street analysts. How have TRVN shares performed in 2023? Trevena's stock was trading at $1.43 at the beginning of 2023. Since then, TRVN stock has decreased by 54.4% and is now trading at $0.6522. View the best growth stocks for 2023 here. Are investors shorting Trevena? Trevena saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,130,000 shares, an increase of 207.5% from the August 31st total of 367,500 shares. Based on an average daily volume of 615,800 shares, the short-interest ratio is currently 1.8 days. Approximately 8.4% of the shares of the stock are sold short. View Trevena's Short Interest. When is Trevena's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our TRVN earnings forecast. How were Trevena's earnings last quarter? Trevena, Inc. (NASDAQ:TRVN) posted its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.24. The biopharmaceutical company had revenue of $3.02 million for the quarter, compared to analysts' expectations of $0.70 million. When did Trevena's stock split? Shares of Trevena reverse split on the morning of Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Trevena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX). What is Trevena's stock symbol? Trevena trades on the NASDAQ under the ticker symbol "TRVN." Who are Trevena's major shareholders? Trevena's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.66%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Barry Shin and Carrie L Bourdow. View institutional ownership trends. How do I buy shares of Trevena? Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Trevena's stock price today? One share of TRVN stock can currently be purchased for approximately $0.65. How much money does Trevena make? Trevena (NASDAQ:TRVN) has a market capitalization of $8.94 million and generates $570,000.00 in revenue each year. The biopharmaceutical company earns $-53,670,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. How can I contact Trevena? Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for the company is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at ir@trevena.com. This page (NASDAQ:TRVN) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.